Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
24AUG

IMU raises £40m to read blood

2 min read
16:40UTC

IMU Biosciences closed an oversubscribed £40m Series A on 2 June, co-led by IQ Capital and Molten Ventures, with the British Business Bank co-investing on its second UK life-sciences cap table inside a fortnight.

← Back to UKRI's sponsor department no longer existsJump to analysis ↓
TechnologyDeveloping
Key takeaway

State capital is now a routine equity co-investor on British biotech cap tables beside specialist funds.

IMU Biosciences closed an oversubscribed £40m ($53m) Series A on Tuesday 2 June. IQ Capital and Molten Ventures co-led, with the British Business Bank (BBB) co-investing. Oversubscribed means investors sought more shares than the company offered. The platform extracts more than 100 million immune-system data points from a single blood sample, so one routine draw could replace a battery of separate immune tests. 1

The BBB had put £12m into Cytospire's £61m Series A in May and £50m into the Longwall deep-tech fund . Its £6.6bn expanded mandate lets it lead and co-invest directly in startups rather than backing them only through fund intermediaries.

That pattern reframes what UK state capital does at this stage. A development bank acting as a backstop appears when private money is absent; the BBB is appearing precisely where private money is already present, sitting beside IQ Capital and Molten on a priced biotech round. State capital is becoming a recurring line on British biotech cap tables rather than a substitute for the funds it sits beside.

Deep Analysis

In plain English

A standard blood test measures perhaps 20-50 different immune markers at once. IMU Biosciences has built a platform that measures over 100 million data points from a single blood sample, a four-to-five order of magnitude jump in resolution. Immune system data is medically useful because immune patterns appear early in many diseases, sometimes before other symptoms. At this density, IMU can identify correlations that simpler assays miss entirely: which patients will respond to a specific immunotherapy, or which immune signatures predict disease progression. The £40m raised funds the clinical validation studies needed to convert that data density into diagnostic products that hospitals and pharmaceutical companies will pay for.

What could happen next?
  • Precedent

    The BBB's third direct life-sciences co-investment in six weeks (Cytospire, Quantum Motion, IMU) establishes a pattern: UK state capital now participates routinely in private biotech rounds as a minority co-investor alongside specialist VCs.

  • Opportunity

    The 100-million-data-point density creates a pharmaceutical partnership opportunity: drug companies running immunology trials can pay per-assay fees for immune profiling at a resolution unavailable elsewhere.

Sources:UK Tech News
Mentions:IQ Capital →British Business Bank →Cytospire Therapeutics →Longwall Ventures →IMU Biosciences →Molten Ventures →
First Reported In

Update #7 · OQC's £260m sets European quantum record

UK Tech News· 7 Jun 2026
Read original →
Causes and effects
Caused by
Cytospire's £61m oncology Series A oversubscribed
BBB's £12m co-investment in Cytospire's Series A in May established the direct BBB biotech co-investor pattern repeated in IMU Biosciences.
Occurred 5 May 2026
Read story →
State £50m backs the tier funds skip
BBB's £50m Longwall deep-tech fund cornerstone in May is part of the same expanded mandate that brought BBB onto IMU's cap table directly.
Occurred 27 May 2026
Read story →
Jobs plan targets the lab-skills gap
The plan addresses the same staffing gap IMU Biosciences' £40m AI-biotech round in June assumed was solved.
Occurred 9 Jul 2026
Read story →
This Event
IMU raises £40m to read blood
The state bank's repeat direct co-investment shows it acting as a routine equity partner in British biotech, not a lender of last resort.
Led to
Neubond seed is Japan VC's UK first
IMU Biosciences' £40m Series A is part of the UK-research-producing-companies pattern Neubond's Japanese-funded seed continues.
Occurred 15 Jun 2026
Read story →
Alchemab wins Bank's record £25m cheque
IMU Biosciences' £40m June round set the AI-biotech benchmark that Alchemab's £25m cheque extends.
Occurred 9 Jul 2026
Read story →
Different Perspectives
Highland Europe
Highland Europe
Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.
Integrity Growth Partners
Integrity Growth Partners
The Los Angeles firm put £16.1m into Prevalent AI on 24 August, the London GCHQ-alumni company's first outside capital, specifically to fund its US expansion. Its stake is a single commercial bet on one UK deep-tech founder's American growth, not a comment on which department UKRI answers to this month.
Temasek
Temasek
Temasek led PhysicsX's Series C on 30 July, into which the British Business Bank put $25m through British Growth Partnership Fund I. State-backed pension capital rides behind a foreign-led growth round while UK weekly tech funding fell 72% to £102.95m across nine rounds three weeks later.
Innovate UK's Women in Innovation cohort
Innovate UK's Women in Innovation cohort
Sixty-one founders won £75,000 grants from Innovate UK on 5 August, the programme's largest-ever cohort, with a further 39 highly commended founders taking support without cash. For these founders the sponsorship dispute over UKRI's parent department is academic: the money and mentoring arrived exactly as scheduled.
Financial Conduct Authority
Financial Conduct Authority
The FCA added five fintechs, ClearScore, Modulr, Teya, Urban Jungle and Zilch, to its Scale-up Unit on 7 August, the first cohort it regulates solely rather than jointly with the Prudential Regulation Authority. The unit's expansion is a routine regulatory build-out running on its own timetable, unconnected to the sponsorship dispute over its sister department UKRI.
Cabinet Office
Cabinet Office
The Cabinet Office ran the DSIT-to-BIST transfer as a standard cross-government machinery change, the kind gov.uk pages and framework documents routinely take months to catch up with after any department is abolished or renamed. Officials treat the paperwork lag as administrative sequencing, not dysfunction: funding and grant-approval layers moved first because they had to keep working.